On March 21, Japan's Health, Labor and Welfare Ministry ordered the company distributing the anti-influenza drug oseltamivir (Tamiflu) in Japan to warn physicians against prescribing the drug to patients aged 10 to 19 years because of reports of neuropsychiatric adverse effects in some children and adolescents who were given the drug. According to reports in the Japanese press, the health ministry said that two 12-year-old boys who had taken oseltamivir were injured after they jumped off the second floor of their homes in February and March; 2 teenagers, both 14 years old, had died in February under similar circumstances.
Stephenson J. Flu Drug Concerns. JAMA. 2007;297(15):1646. doi:10.1001/jama.297.15.1646-a
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: